ClinicalTrials.gg
RecruitingNCT07854782Updated Nov 5, 2026

Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Phase 3 interventional study of ALN-CIDEB and Placebo in Metabolic Dysfunction-Associated Steatotic Liver Disease and MASLD, sponsored by Regeneron Pharmaceuticals. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Planned enrollment
10th of 460
1,500 · median 56
Started
2026
with 7 others
Phase 3
29 of 547
7 open now
Primary completion
2029-03
later than 74 of 92 live
Registered
547th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 10th largest by planned enrollment of the 460 interventional ones that give a count, is one of 8 that started in 2026, is one of 29 in phase 3, reaches primary completion later than 74 of the 92 other live ones, and was the 547th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). MASH is more advanced stage of a broader liver disease, MASLD. MASLD is a liver condition caused by too much fat building up in the liver. This can lead to liver scarring and inflammation and can reduce the liver's ability to keep the body healthy. Cell death-inducing DFFA-like effector B (CIDEB) is a protein made by liver cells that helps the liver to store fat.

The study is looking at:

  • What side effects ALN-CIDEB might cause
  • How well ALN-CIDEB works to change liver fat, liver injury, and liver scarring
  • How ALN-CIDEB could affect the body and the liver, which can help researchers understand why ALN-CIDEB works better for some people than others
03

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • MASLD

Keywords

  • NAFLD
  • NASH
  • Metabolic Dysfunction-Associated Steatohepatitis
  • MASH
  • Fatty Liver Disease
  • Non-alcoholic Fatty Liver Disease
  • Liver Fibrosis
  • Steatotic Liver Disease
  • SLD
  • Metabolic Fatty Liver Disease
  • Hepatic Steatosis
  • Fatty Liver
  • Liver Fat
  • Excess Liver Fat
  • Obesity
  • Insulin Resistance
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has a clinical diagnosis of MASLD, as defined in the protocol
  2. Has a liver stiffness measurement between 6 and 20 kilopascals (kPa), as measured by a FibroScan® scan during screening or within approximately 3 months of screening, as defined in the protocol

Key Exclusion Criteria:

  1. Has a known chronic liver disease other than MASLD, as determined by the investigator, as defined in the protocol
  2. Has prior or current suspected or known drug-induced liver injury within approximately 1 year prior to screening
  3. Has a history of liver transplantation, current placement on a liver transplant list, or Model for End-Stage Liver Disease (MELD) score >12
  4. Has a known history of alcohol or other substance abuse within the last year or at any time during screening based on investigator's discretion
  5. Has prior, current, or planned future use (during the treatment period) of a GLP-1 receptor agonist-based therapy or any medication approved for the treatment of MASH (eg, resmetirom) unless used at a generally stable dose and regimen since at least 3 months prior to screening visit and throughout the screening period with no change to the dose or regimen anticipated during the treatment period, as defined in the protocol
  6. Has evidence of uncontrolled (HIV) infection, virus (HBV) infection, or virus (HCV) infection during screening, as defined in the protocol

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    ALN-CIDEB Dose Level 1

    Drug: ALN-CIDEB

  • Experimental
    ALN-CIDEB Dose Level 2

    Drug: ALN-CIDEB

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugALN-CIDEB

    Administered per the protocol

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Through Week 64

  2. Severity of TEAEs

    Time frame: Through Week 64

Secondary outcomes

  1. Change from Baseline in FibroScan Controlled Attenuation Parameter (CAP)

    Time frame: At Week 52

  2. Change from Baseline in FibroScan Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE)

    Time frame: At Week 52

  3. Change from Baseline in Aspartate Aminotransferase (AST)

    Time frame: Through Week 64

  4. Change from Baseline in Alanine Aminotransferase (ALT)

    Time frame: Through Week 64

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 28 months after the start.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 28 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Oct 28, 2026was Nov 2026
Primary completionEst.
Mar 3, 2029
CompletionEst.
Mar 3, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Advanced Medical Trials · Georgetown, United States
  • Med Research of Florida, LLC · Miami, United States
  • Tandem Clinical Research · Marrero, United States
  • Tandem Clinical Research · Metairie, United States
across 2 updates, Nov 2, 2026 – Nov 5, 2026
Start date
Nov 6, 2026→Oct 28, 2026 (actual)
Nov 2, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Nov 5, 2026
    3 sites added
    Show 3 added (3 United States)
    • Med Research of Florida, LLC · Miami, United States
    • Tandem Clinical Research · Marrero, United States
    • Tandem Clinical Research · Metairie, United States
    + 1 other change: verification date
  2. Nov 2, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Advanced Medical Trials · Georgetown, United States
    Start date Nov 6, 2026→Oct 28, 2026 (now actual)
    + 1 other change: verification date
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854782
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 28, 2026
Primary completion
Mar 3, 2029 (estimated)
Completion
Mar 3, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion